Merchandising at Nine West Retail Stores

Ananth   Raman; Colin S  Welch

Case | HBS Case Collection | May 1998 (Revised May 2001)

Merchandising at Nine West Retail Stores

by Ananth Raman and Colin S Welch

Abstract

Describes the merchandising decision process (organization, structure, and incentives) at Nine West retail stores, a large footwear retailer in the United States. Also describes changes currently occurring at Nine West and thus provides a context in which students can recommend changes to the merchandising process and the structure of the merchandising organization. To explain how merchandising decisions are made at a fashion retailer and to explore how changes in the environment will impact the merchandising organization.

Keywords: Organizational Structure; Situation or Environment; Motivation and Incentives; Decision Making; Change; Budgets and Budgeting; Forecasting and Prediction; Brands and Branding; Marketing Strategy; Product Marketing; Retail Industry; Apparel and Accessories Industry; United States;

Language: English

Format: Print

17 pages

Educators Purchase

Citation:

Raman, Ananth, and Colin S Welch. "Merchandising at Nine West Retail Stores." Harvard Business School Case 698-098, May 1998. (Revised May 2001.)

Celebrated as one of the world's premiere luxury hotel brands, Oberoi Hotels attracts and serves some of the most quality sensitive guests in the world. The case considers the challenge of how an organization with a standardized service model can repeatedly delight customers whose expectations grow with every interaction. To explore this question, the case details the design elements of Oberoi's complex service operation, including its approaches to employee management and continuous improvement, as well as the dynamics of service competition in a rapidly growing market.

In 2016, David Hysong, at age 27, found out he had a rare, incurable cancer. Rather than wait around to die, Hysong, a recent graduate of Harvard Divinity School, decided to launch a biotechnology company called Shepherd Therapeutics to development treatments for his and other rare cancers. Two years later, the company had several drugs in promising stages of development but were at least 3 to 5 years away from commercialization, if they made it through clinical trials successfully. Only about 4% of drugs that enter clinical trials receive U.S. FDA approval. It is October 2018, and Shepherd is running out of money. Hysong needs to raise $5 million to fund operations for 2019 and at least $20 million for the following few years. But the company is too early to attract the type of venture capital he needs. Even if he got financing, Hysong worried that the company’s mission could be compromised by investors more interested in a return on their investment than saving lives, and he worried about the scaling challenges ahead.

Faculty & Research

Merchandising at Nine West Retail Stores

Abstract

Citation:

About the Author

More from the Author